<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24948">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766414</url>
  </required_header>
  <id_info>
    <org_study_id>36688</org_study_id>
    <secondary_id>2011-002222-46</secondary_id>
    <nct_id>NCT01766414</nct_id>
  </id_info>
  <brief_title>In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II</brief_title>
  <acronym>VECTORII</acronym>
  <official_title>In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excessive inflammation is associated with tissue damage caused by over-activation of the
      innate immune system. This can range from mild disease to extreme conditions, such as
      multiple organ dysfunction syndrome (MODS) and acute respiratory distress (ARDS). In marked
      contrast to adaptive immunity which is very sensitive to immune modulators such as steroids,
      the innate immune system cannot be sufficiently targeted by currently available
      anti-inflammatory drugs.

      The investigators hypothesize that pre-treatment with C1-esterase inhibitor in a human
      endotoxemia model can modulate the innate immune response.

      In this study, human endotoxemia will be used as a model for inflammation. Subjects will,
      prior to endotoxin administration, receive C1 esterase inhibitor or placebo. Blood will be
      sampled to determine the levels of markers of the innate immune response.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Neutrophil phenotype and redistribution</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokines and other markers of inflammation</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C1-inhibitor and complement concentration and activity</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Innate Immune Response</condition>
  <condition>Endotoxemia</condition>
  <condition>Inflammation</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-esterase inhibitor</intervention_name>
    <description>intravenously</description>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <other_name>Cetor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>intravenously</description>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>2 ng/kg E. coli reference endotoxin 11:H 10:K negative</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers (18-35 years old)

        Exclusion Criteria:

          -  Relevant medical history

          -  Drug-, nicotine-abuses

          -  Tendency towards fainting

          -  Hyper- or hypotension

          -  Use of any medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Pickkers, MD, PhD</last_name>
    <email>p.pickkers@ic.umcn.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Pickkers, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>January 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1</mesh_term>
    <mesh_term>Complement C1s</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
